Novel combination achieves 60.8% response rate and 90.2% disease control rate in first-line non-small cell lung cancer (1L ...

Merck (MRK) stock gains as its bestselling drug, Keytruda, as part of a combination regimen, succeeds in a Phase 3 trial for ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

Exelixis delivers a strong Q1 performance with raised 2025 guidance, robust Cabometyx sales, and share buybacks. Read the ...

The funds will support multiple new and ongoing clinical trials of Tilt's oncolytic adenoviral therapy TILT-123.